Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The indication of chemotherapy of 2nd line treatment in advanced non small cell lung cancer
is now well established. The two treatments of reference are pemetrexed (alimta) and
docetaxel (taxotere). Effectiveness and toxicity of the two drugs are largely documented in
the literature.
Economic analyses are currently one of the criteria used in medical decision, beside
effectiveness, quality of life and toxicities.
However, Economical comparison shows significant variations in the acquisition costs of the
two drugs. Consequently, it appears interesting to carry out a randomized prospective study
with on exclusive economical criteria of judgment.
As there is no difference in the effectiveness between the two treatments, a
cost-minimization analysis will be carried out to appreciate the ratio benefit/risks from an
economical point of view (payer).